#Bioprocessing 4.0

[lanettcdmo]

The Future of Pharmaceutical Contract Manufacturing Services: Trends & Innovations

Pharmaceutical Contract Manufacturing Services (PCMS) have become an essential component of the global healthcare ecosystem. As pharmaceutical companies seek to optimize costs, ensure compliance, and accelerate time-to-market, outsourcing manufacturing to specialized contract development and manufacturing organizations (CDMOs) has gained momentum. In this blog, we explore the latest trends shaping the future of pharmaceutical contract manufacturing services.

1. Growth of Biologics & Biosimilars

Biopharmaceuticals, including monoclonal antibodies, gene therapies, and biosimilars, are driving the demand for specialized contract manufacturing services. CDMOs are investing in advanced bioprocessing technologies and bioreactors to support the complex production of these therapies.

2. Adoption of Continuous Manufacturing

Traditional batch manufacturing is being replaced by continuous manufacturing (CM), offering increased efficiency, reduced waste, and enhanced scalability. CM enables real-time quality monitoring, improving overall product consistency and safety.

3. Emphasis on Regulatory Compliance & Quality Standards

With stringent regulations from the FDA, EMA, and other global authorities, CDMOs are focusing on compliance with Good Manufacturing Practices (GMP) and data integrity. Digitalized record-keeping, automation, and AI-powered analytics are enhancing regulatory adherence.

4. Integration of Digital & Smart Manufacturing

Industry 4.0 is transforming pharmaceutical contract manufacturing services with AI, IoT, and blockchain. Smart factories with predictive maintenance, automated workflows, and supply chain transparency are becoming the industry standard.

5. Growth of Specialized & Niche CDMOs

As personalized medicine and rare disease treatments gain prominence, niche CDMOs specializing in small-batch, high-potency, and orphan drug manufacturing are emerging. These companies offer tailored solutions to biotech and pharmaceutical firms.

6. Expansion of Global Manufacturing Networks

Pharmaceutical companies are diversifying their supply chains by partnering with CDMOs across different regions. This mitigates risks related to geopolitical instability, trade regulations, and supply chain disruptions.

7. Sustainability & Green Manufacturing

The industry is shifting towards eco-friendly manufacturing practices. Sustainable solvents, energy-efficient processes, and waste reduction strategies are being adopted to minimize the environmental footprint of pharmaceutical production.

Final Thoughts

Pharmaceutical contract manufacturing services are evolving rapidly, driven by technological advancements, regulatory requirements, and market dynamics. Companies that embrace these trends and invest in innovation will lead the next phase of growth in the pharmaceutical outsourcing sector.

[ashwetu]

Meticulous Research® Releases New Report on Biopharmaceutical Processing Equipment and Consumables Market: Projected to Reach $83.39 Billion by 2031

Meticulous Research®, a globally recognized market intelligence firm, has published a new report forecasting significant growth in the Biopharmaceutical Processing Equipment and Consumables Market. The market is expected to achieve a compound annual growth rate (CAGR) of 9.5% during the forecast period, reaching an estimated $75.72 billion by 2031.

The upward trajectory of this market is largely driven by the expanding biopharmaceutical sector, ongoing biopharmaceutical plant capacity expansions, and the increasing adoption of single-use bioprocessing equipment. However, the market's growth faces headwinds due to the inherent complexities associated with the development and manufacturing of biopharmaceuticals. Despite these challenges, the market presents lucrative opportunities, particularly in emerging economies, as demand for biopharmaceuticals rises, and the industry transitions toward Bioprocessing 4.0 and personalized medicine. Conversely, the substantial capital investment required for biopharmaceutical production remains a critical challenge for market participants.

Top Industry Players : https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

The report also provides a comprehensive analysis of the leading companies in the Biopharmaceutical Processing Equipment and Consumables Market, including:

Thermo Fisher Scientific Inc. (U.S.) Headquartered in Massachusetts, Thermo Fisher Scientific operates through four business segments, with its BioProduction segment playing a pivotal role in the biopharmaceutical market. The company’s extensive global presence includes operations across North America, Europe, Asia-Pacific, and other regions.

Agilent Technologies, Inc. (U.S.) Based in California, Agilent Technologies offers a wide range of biopharmaceutical processing equipment through its Life Sciences and Applied Markets business segment. The company’s products are essential for analyzing biological properties in the biopharmaceutical sector.

Sartorius AG (Germany) Sartorius AG, headquartered in Göttingen, Germany, provides a diverse portfolio of products through its Bioprocess Solutions segment. The company maintains a strong global presence, with facilities in key regions such as Europe, North America, and Asia.

Danaher Corporation (U.S.) Operating globally, Danaher Corporation is a leading provider of life sciences and diagnostics products. The company’s Life Sciences segment offers critical biopharmaceutical processing equipment and consumables.

Merck KGaA (Germany) With a legacy dating back to 1668, Merck KGaA operates through its Life Sciences segment to provide innovative solutions in the biopharmaceutical processing market. The company’s extensive global footprint includes operations in over 50 countries.

Additional key players profiled in the report include 3M Company, Bio-Rad Laboratories, Inc., Eppendorf SE, Solaris Biotechnology Srl, and Repligen Corporation, among others. These companies are instrumental in driving innovation and addressing the evolving needs of the biopharmaceutical industry.

Top 10 Blog Here :   https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

Market Insights

Meticulous Research®’s report provides a detailed analysis of market trends, opportunities, and challenges. The report examines critical factors influencing market growth, including the adoption of new technologies, strategic partnerships, and evolving regulatory landscapes. It also explores regional market dynamics, highlighting growth prospects in North America, Europe, Asia-Pacific, and other regions.

For Further Information

To gain a deeper understanding of the Biopharmaceutical Processing Equipment and Consumables Market, download the full report from Meticulous Research®.

Contact Information: Meticulous Research® Email: sales@meticulousresearch.com Phone: +1-646-781-8004 Connect with us on LinkedIn

[sunalimerchant]

The Future of Chemical Engineering Jobs: Emerging Trends and Opportunities

Chemical engineering is a dynamic and versatile field that continually evolves with advancements in technology, changes in industry demands, and global economic shifts. As the world faces new challenges and opportunities, the landscape of chemical engineering jobs is also transforming. This article explores the emerging trends and opportunities in chemical engineering recruitment, providing insights into what the future holds for aspiring and current chemical engineers.

The Shift Towards Sustainability

One of the most significant trends shaping the future of chemical engineering jobs is the growing emphasis on sustainability. With increasing awareness of environmental issues and the need for sustainable practices, chemical engineers are at the forefront of developing green technologies and processes. This shift is driving demand for professionals who can innovate in areas such as renewable energy, waste reduction, and sustainable materials.

Chemical engineers with expertise in bioengineering, environmental engineering, and sustainable design are particularly sought after. Companies are looking for candidates who can help them reduce their carbon footprint, improve energy efficiency, and develop eco-friendly products. As a result, sustainability is becoming a crucial focus in chemical engineering recruitment.

Advancements in Biotechnology

Biotechnology is another area experiencing rapid growth, offering numerous opportunities for chemical engineers. The integration of biology and chemical engineering is leading to breakthroughs in pharmaceuticals, healthcare, and agriculture. Chemical engineers are essential in designing processes for large-scale production of biopharmaceuticals, developing biofuels, and creating genetically modified organisms (GMOs) for enhanced agricultural productivity.

As biotechnology continues to expand, chemical engineering recruitment is increasingly targeting candidates with skills in bioprocessing, molecular biology, and bioinformatics. This intersection of disciplines is creating new career paths and expanding the traditional boundaries of chemical engineering.

Digital Transformation and Industry 4.0

The advent of Industry 4.0 is revolutionizing the manufacturing and chemical industries through digital transformation. Technologies such as artificial intelligence (AI), machine learning, the Internet of Things (IoT), and big data analytics are being integrated into chemical engineering processes to enhance efficiency, productivity, and safety.

Chemical engineers now need to be proficient in data analysis, automation, and digital tools. This trend is leading to a demand for professionals who can navigate and implement these technologies in chemical processes. Chemical engineering recruitment is increasingly focused on candidates with a strong foundation in both traditional engineering principles and modern digital skills.

The Rise of Specialty Chemicals

The specialty chemicals sector, which includes high-value products such as pharmaceuticals, agrochemicals, and performance chemicals, is experiencing significant growth. Unlike bulk chemicals, specialty chemicals are produced in smaller quantities but with higher profit margins. This sector's expansion is creating new job opportunities for chemical engineers in research and development, process engineering, and quality control.

Chemical engineering recruitment in this sector emphasizes innovation and technical expertise. Companies are seeking engineers who can develop new formulations, optimize production processes, and ensure regulatory compliance. The ability to work on diverse and complex projects makes this an exciting and rewarding area for chemical engineers.

Globalization and International Opportunities

Globalization continues to shape the chemical engineering job market, offering international career opportunities. Multinational companies are looking for chemical engineers who can work in different regions and adapt to various cultural and regulatory environments. This trend is particularly evident in emerging markets, where rapid industrialization and urbanization are driving demand for engineering talent.

Chemical engineering recruitment is increasingly global, with companies seeking candidates who are flexible, adaptable, and willing to relocate. Proficiency in multiple languages and an understanding of global market dynamics can give candidates a competitive edge in this globalized job market.

Conclusion

The future of chemical engineering jobs is marked by exciting trends and opportunities. The focus on sustainability, advancements in biotechnology, digital transformation, the rise of specialty chemicals, and globalization are all shaping the landscape of chemical engineering recruitment. Aspiring and current chemical engineers must stay abreast of these trends, continuously update their skills, and be open to new challenges and opportunities.

As the field evolves, chemical engineers will play a pivotal role in addressing some of the world's most pressing issues, from environmental sustainability to healthcare innovation. By understanding and embracing these emerging trends, chemical engineers can position themselves for success in this dynamic and ever-changing industry.

[bisresearchreports]

The global digital biomanufacturing market is expected to reach $55,564.9 million by the end of 2031. The market is expected to grow at a CAGR of 13.12% during the forecast period from 2022 to 2031.

[metiresearchinfo]

TOP 10 COMPANIES IN CONTINUOUS BIOPROCESSING MARKET

The continuous bioprocessing market is expected to grow at a CAGR of 23.0% from 2021 to reach $429.12 million by 2028.

The growth of global continuous bioprocessing market is primarily driven by factors such as recent product launches in the continuous bioprocessing space, gradual adoption of continuous manufacturing, and global initiatives supporting the adoption of biopharmaceuticals. The shift towards bioprocessing 4.0, untapped markets in developing countries, and rising adoption of personalized medicines are expected to offer significant market opportunities.

Here are the top 10 companies operating in continuous bioprocessing market

3M Company

3M is a multinational conglomerate with expertise in product development, manufacturing, and marketing across various industries like consumer care, industrial safety, healthcare, and others. The company manages its operations across four business segments: Transportation and Electronics, Safety and Industrial, Consumer, and Health Care. The Health Care business segment offers oral care solutions, medical solutions, health information systems, separation and purification sciences, food safety, and drug delivery system. Separation and purification sciences include a comprehensive range of filtration products intended for the separation, classification, and purification of gases and fluids. The company provides a range of chromatography filters for biopharmaceutical applications like vaccines, recombinant proteins, chemical pharmaceuticals, and plasma fractionation.

3M sells its products through a number of distribution channels, including numerous ecommerce, retailers, traditional wholesalers, jobbers, dealers, and distributors and directly to users. The company operates 64 manufacturing facilities across 29 states in the U.S. Internationally, the company has over 97 manufacturing and converting facilities in 35 countries.

Cytiva

Cytiva is a provider of services and technologies to advance and accelerate the development and production of therapeutics. Previously, the biopharma business of GE Healthcare Life Sciences (U.S.), Cytiva is now a part of Danaher Corporation. The company offers its solutions for bioprocessing, cellular analysis, cell and gene therapy, diagnostics, enterprise solutions, genomics, lab filtration, and protein research. The company’s portfolio of bioprocessing solutions consists of upstream and downstream bioprocessing, enterprise solutions for bioprocessing, and FastTrack bioprocessing services. Upstream and downstream bioprocessing involves solutions for improving Xcellerex bioreactors, HyClone cell culture media, MabSelect chromatography resins, and ÄKTA systems. Enterprise solutions for bioprocessing involve KUBio facilities and Modular FlexFactory platforms for integrated platforms. FastTrack bioprocessing services include process development, collaborative training, and manufacturing services.

Cytiva has its presence across 40 locations covering North America, Europe, Asia, Latin America, and the Middle East, and Africa. As per the company’s data, in 2019, over 75% of biological therapies approved by the U.S. FDA used Cytiva’s technology for manufacturing.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc. is a biotechnology company primarily engaged in accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics, and increasing laboratory productivity. The company operates through its four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company’s life science segment consists of bioscience, genetic sciences, clinical next generation sequencing, and bioproduction. The company’s bioproduction offering includes single use bioproduction solutions, production cell culture media solutions, chromatography products, rapid molecular products, and scalable solutions for the manufacturing of cell therapy-based drugs.

The company sells and markets its products and services through electronic commerce, direct sales force, third party distributors, and customer service professionals. The company serves over 400,000 customers working in the biotech and pharma space, diagnostic labs, hospitals and clinics, research institutions, government agencies, universities, and environmental, industrial quality, and process control settings.

Merck KGaA

Merck KGaA is a science and technology company aimed to improve the health and wellbeing of people and advance their lives through science and technology. The company operates its business through three segments: Healthcare, Life Sciences, and Performance Materials. The Life Sciences business segment is further categorized into Research Solutions, Process Solutions, and Applied Solutions. Process solutions provide drug manufacturers with process development technologies and expertise, including continuous bioprocessing. The company operates in the continuous bioprocessing market through its Process Solutions business unit (a part of the Life Sciences segment).

The Life Science business sector has 59 manufacturing sites across the globe and more than 100 distribution centers. The sector has corporate offices, manufacturing units, and distributors across Argentina, Germany, France, Romania, Colombia, Japan, Brazil, Belgium, Croatia, the U.S., and Iraq, among others. The company’s life science segment serves various clients catered across a range of geographies, namely, North America, Europe, Asia Pacific, MEA, and Latin America.

Sartorious AG

Sartorious AG, assists biopharma research and development and manufacturing companies. The company conducts its operations through two divisions: Lab Product and Services and Bioprocess Solutions. The Bioprocess Solutions division offers products and services for biopharma production. Some of the technologies under Bioprocess Solutions include cell line technologies, bioreactors, cell culture media, products for the separation, purification and concentration, and storage and transportation products.

The company markets its products directly through sales representatives. The company expanded its direct sales operations in the Asia Pacific with the acquisition of a sales partner in Taiwan in 2012, particularly from Bioprocess Solutions. The company’s Bioprocess Solutions segment has a well-developed production network, with the largest production sites located across France, Germany, and Puerto Rico. The company also manufactures in Switzerland, India, the U.K., Tunisia, and the U.S.

Repligen Corporation

Repligen Corporation is a global life science company specializing in the development and commercialization of innovative bioprocessing technologies and systems, increasing flexibility and efficiencies in biologics manufacturing. The company’s bioprocessing business involves four main franchises: Filtration, Chromatography, Process Analytics, and Proteins. The chromatography franchise includes products for development, downstream purification, manufacturing, and quality control of biologics. The company entered the filtration technology market in 2014 after the acquisition of XCell Alternating Tangential Flow (“ATF”) assets from Refine Technology LLC (U.S.), which have applications in continuous cell culture processing. The company also has a portfolio of process analytics products complementing its product offering. Further, through the proteins segment, the company assists upstream bioprocessing.

The company’s bioprocessing products are majorly sold to biopharmaceutical development companies, life sciences companies, and contract manufacturing organizations. The company’s manufacturing facilities are located in Waltham, Massachusetts; Rancho Dominguez, Marlborough, Massachusetts, Texas; California; Irving, Lund, Sweden; Bridgewater, New Jersey; and Weingarten, Germany.

Eppendorf AG

Eppendorf AG is a life science company involved in the manufacturing and selling of laboratory instruments, consumables, and services. The company operates in four business segments: Separation & Instrumentation, Consumables, Liquid Handling, and Lab Solutions, under which it manufactures and sells products like manual and automatic pipettes, centrifuges, dispensers, spectrometers, mixers, DNA amplification equipment, fermenters and bioreactors, ultra-low temperature freezers, shakers, CO2 incubators, cell manipulation systems, single use bioreactor systems and consumables like test tubes, microtiter plates, and pipette tips.

The company has a direct presence in about 26 countries, and it is present in all other markets through distributors. As a part of the innovation initiative, the company had undertaken agile product development across its global operations in 2019, under which the company introduced about 20 products in 2019.

Applikon Biotechnology

Founded in 1973 and is headquartered in the Netherlands, Applikon Biotechnology develops and supplies advanced bioreactor systems from lab scale to pilot and production scale. The company supports the pharma industry and industrial microbiology in upstream processing by implementing scalable platforms from initial screening through full scale development. The company offers cultivation systems, process controls, software, turnkey systems, process analytics, perfusion, and integrated solutions for various industries like bio-fuels, pharma, regenerative medicine, academia, and food. The company’s Applikon BioSep System is a cell retention device for high quality perfusion processes, which uses a high frequency resonant ultrasonic waves for cell separation instead of physical membrane or mesh.

The company underwent facility expansion in June 2017. The company has a global distribution network covering over 35 countries. In December 2019, the company announced an acquisition of 100% shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V. The company has an annual sale of USD 47.61 million (SEK 450 million)

Pall Corporation

Pall Corporation is a manufacturer of high tech separation, filtration, and purification instruments serving diverse needs of customers for various application industries. Pall Life Sciences and Pall Industrial are the primary operating segments of the company. The company’s life sciences business provides products and services that support the discovery, development, and production of medicinal products, including vaccines, biotech drugs, cell therapies, and pharmaceuticals. The life science offerings include depth filtration, sterile filtration, chromatography hardware, and purification platform, and bio containers.

The company is present across 80 locations worldwide. In 2015, Danaher Corporation (U.S.) completed the merger of U.S. based Pentagon Merger Sub, Inc, after which an indirect wholly owned subsidiary of Danaher Corporation, Pall Corporation, was formed.

Bionet

Incorporated in 1999 and headquartered in Mercia, Spain. Bionet is a manufacturer of laboratory, pilot, and industrial equipment and software for the bioprocessing industry. The company also provides bioprocess related services for the companies providing biomolecules through the cell culturing process and microbial fermentation. The company’s portfolio of bioprocessing solutions includes automation software solutions, bioreactors/fermenters, auxiliary equipment like cleaning in place systems, and tangential filtration. For industrial clients, the company provides complete bioproduction plants, integrating the company’s proprietary equipment with technologies like centrifuges, homogenizers from other vendors. The company also provides services like operation and maintenance activity, qualification, and technology election. Bionet is also part of international R&D institutions, organizations, and projects such as CETENMA, ASEBIO, CITEM, BRIDGE2020, GREENPGAS, PROGRAMA “HORIZONTE PYME”, GREEN PROTEIN, and FABRICACIÓN DEVACUNAS. The company has also been ISO 9001:2015, certified by AENOR for its quality management systems.

Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/download-sample-report/cp_id=5079

Authoritative Research on the Continuous Bioprocessing Market – Global Opportunity Analysis and Industry Forecast (2021-2028)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

Recent financial performance

Key products

Significant company strategies

Partnerships and acquisitions

The Impact of COVID-19 on the Continuous Bioprocessing Market

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

Please download report pages and learn more:

Download Free Samlpe

[adalidda]

Illustration Photo: The hybrid cloud will enable a flexible infrastructure of emerging technologies to supercharge the discovery of materials, some of which we haven’t imagined yet. Inside the IBM Cloud in Dallas, Texas. (Credit: Connie Zhou for IBM / Flickr Creative Commons Attribution-NoDerivs 2.0 Generic (CC BY-ND 2.0))

Strategic Digital and Health Technologies

The EIC Accelerator Challenges supports companies (principally start-ups and SMEs) to scale up high impact innovations with the potential to create new markets or disrupt existing ones in identified areas of strategic relevance. Like EIC Accelerator Open (Section II.3 of the EIC Work Programme 2021), the EIC Accelerator Challenges focus on innovations building on scientific discovery or technological breakthroughs (‘deep tech’) and where significant funding is needed over a long timeframe before returns can be generated (‘patient capital’).

The EIC Accelerator Challenges is open to innovations in the specific fields of technology or application described by the specific challenges in sections III.3.1 and III.3.2 of the EIC Work Programme 2021. However, innovations that harm the environment or social welfare or that are designed primarily for military applications will not be supported.

You should apply to the EIC Accelerator Challenge – Strategic Digital and Health Technologies, if you believe that your company has the potential to be a global leader in developing strategic technologies in one of the following areas:

Digital technologies: devices, methods, systems as well as working principles, processes and standards1 which apply to the ICT technology industry such as advanced high performance computing, edge computing, quantum technologies, cybersecurity, artificial intelligence, block-chain, cloud infrastructure technologies and technologies for the Internet of Things

Healthcare technologies: AI-driven tools for early diagnosis; point-of-care diagnostics; novel approaches in cell and gene therapy, in particular for cancer; development of novel biomarkers for clinical prognosis, patient stratification or monitoring purposes across a wide spectrum of disorders; bioprocessing 4.0 (digitalisation across stages of biodevelopment in biotech/biopharma industry); healthcare intelligence services; and e-health (including mobile health) solutions for healthcare systems, medical practice and Intensive Care Units.

Application Deadline: 9 June 2021 17:00:00 Brussels time

Check more https://adalidda.com/posts/2JBth8g6iiPL2CDz4/strategic-digital-and-health-technologies

[linhgd9]

Bioprocess Bags Critical Insights, Trends, Worldwide Outlook & Forecast Till 2030

Attributed to the economic and operational benefits of bioprocess bags, they have been widely adopted in the biopharmaceutical sector for various bioprocessing applications. This positive scenario is projected to continue, as currently, over three-fourth biotech companies use some kind of single-use technology devices, and are set to increase consumption over the years.

Owing to increased demand, bioprocess bags currently account for nearly one-third of the global single-use technology devices market. Use of bioprocess bags reduces leak points and chances of contamination, making them an ideal choice over conventional stainless steel containers. These advantages are poised to fuel the growth of the bioprocess bags market, which is slated to close in on a market valuation US$ 3 Bn by 2030-end.

To remain ‘ahead’ of your competitors, request for a sample –  https://www.factmr.com/connectus/sample?flag=S&rep_id=3926

Key Takeaways from Bioprocess Bags Market Study

On the basis of type, 2D bioprocess bags have remained the preferred choice in global bioprocess bags market, and generated a market value worth US$ 880 Mn in 2019.

In response to increasing demand for biopharmaceuticals, biotech companies are scaling up their production capacities, which will drive demand for 3D bioprocess bags.

Small- and medium-sized bioprocess bags account for a leading share in the global bioprocess bags market, and are set to generate an absolute $ opportunity worth US$ 1.1 Bn by 2030.

On the basis of application, the chromatography feed & collection segment is poised to expand at a leading growth rate of 10% over the forecast period.

Attributed to the range of bioprocessing applications, the biotechnology end-use industry accounted for over three-fourth of global consumption in 2019.

The United States is projected to remain a leading consumer of bioprocess bags during the forecast period, surpassing a market valuation worth US$ 1.2 Bn by 2030.

“The coronavirus outbreak and failure of conventional pharmaceutical drugs have resulted in huge investments in biotech industries, which will create huge demand for bioprocess bags till the mid-term forecast period,” says a Fact.MR analyst.

Access Research Methodology Prepared By Experts –  https://www.factmr.com/connectus/sample?flag=RM&rep_id=3926

Targeted Acquisition Strategies by Players to Fuel Market Growth

Players in the bioprocess bags market space have been strategically focusing on high potential bioprocess bags, and in response, they have invested millions of dollars in acquiring companies across different geographical regions. Under their targeted strategy, prominent players have acquired numerous competitors to strengthen their market position.

For instance, Sartorius AG acquired selected assets of the life science business of Danaher Corporation in 2020, to enhance its position in the global biopharma market.

In 2019, ThermoFisher strategically acquired two companies – API manufacturing company named Glaxo-Smith-Kline, and Brammer Bio, a viral vector manufacturer.

Such strategies will assist stakeholders to progress in the global bioprocess bags market over the forecast period.

More Valuable Insights on Bioprocess Bags Market

Fact.MR, in its new offering, presents an unbiased analysis of the global bioprocess bags market, presenting historical demand data (2015-2019) and forecast statistics for the period of 2020-2030. The study divulges essential insights on the bioprocess bags market on the basis of type (2D and 3D), capacity (small, medium, large, and extra-large), application (buffer & media storage, cell culture, cell separation & harvest, chromatography feed & collection, ultrafiltration & diafiltration, intermediate & final product hold, and others) and end-use industry (biotechnology and pharmaceuticals), across six major regions.

Connect To An Expert –  https://www.factmr.com/connectus/sample?flag=AE&rep_id=3926

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact: US Sales Office : 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E-Mail: sales@factmr.com

Corporate Headquarter: Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates

from NeighborWebSJ https://ift.tt/3fpE8fN via IFTTT

from WordPress https://ift.tt/3u0Ei1b via IFTTT

[wiseguy-reports]

The highly regulated nature of the biopharmaceutical industry, complemented by the complexity of biological production processes has delayed the entry of Industry 4.0 in this sector. Moreover, the need to transform legacy systems and obtain fresh validations for new ones or those processes requiring any modifications are additional obstacles. Nevertheless, the long-term merits offered by smart manufacturing and digitization in bioprocessing are driving this market.

[fmireports2020]

Automated Cell Culture Systems Market to Reap Excessive Revenues by 2030

According to Future Market Insights, the Automated Cell Culture Systems Market will exhibit a strong CAGR of 8% from 2020-2030.

Escalating incidences of chronic ailments have spurred greater research in cytology and cell biology for developing advanced diagnosis and treatment. This is largely an end-product of boundaries in conventional pharmaceuticals. Furthermore, growing complexities of the nature of chronic diseases is prompting various technological advancements with regard to treatment, thereby bolstering the scope of automated cell culture systems.

Greater penetration of 3D-cell cultures have significantly boosted the adoption of automated culture systems, as is the need for faster testing of biological or biochemical activities. Furthermore, requirement of cell lines to devise vaccines for COVID-19 shall catapult the automated cell culture market in the upcoming forecast period.

"Key players are developing specific and specialty growth media with the aid of various technological advancements, which is expected to sustain market growth over the following decade," infers an FMI analyst.

Key Takeaways from FMI's Automated Cell Structure Systems Report

Increasing applications of cell lines in drug discovery to heighten growth prospects

Infinite cultures to capture three-quarters of the global market share from 2020-2030

Consumables to capture 3/5th of the revenue pie, to reach US$ 11 Bn by 2030

Biotech companies shall be the primary end-users of automated cell structure systems in the coming years

North America shall surge at a CAGR of 6% through 2030, capturing over 2/5th of the market share

To get the sample copy of report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7860

Automated Cell Culture Systems Market- Key Trends

Market players push for innovative culture systems in the wake of augmented research on sera, cell culture media and reagents

Sustainable vessel solutions in packaging through the use of glass and recyclable plastic is influencing manufacturing decisions of market players

Oncology drug development is making exhaustive usage of automated cell structure systems

COVID-19 shall spur advanced research in cell lines application for drug and vaccine development, thus stimulating growth

Automated Cell Culture Systems Market- Region-wise Analysis

East Asia shall emerge as the most lucrative automated cell structure systems market. Increased healthcare infrastructure development is a key reason

North America and Europe to jointly account for 60% of the global market revenue due to the presence of a robust laboratory infrastructure

Automated Cell Culture Systems Market- Competitive Landscape

Prominent players are concentrating on offering new products, innovations and collaborations with other companies to widen their outreach across major geographical areas.

For instance, in July 2020, Sphere Fluidics announced a partnership with the Heriot-Watt University in Edinburgh for developing next generation droplet generator instrumentation. This agreement is for expanding its advanced biologics discovery and therapeutic cell line development.

Also, in February 2020, Selexis announced the application of Bioprocessing 4.0 by incorporating automated systems such as the ambr and Beacon optofluidic platforms for enhanced cell line development.

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-7860

Automated Cell Culture Systems Market Taxonomy

Product Type

Automated Cell Culture Storage Equipment

Automated Cell Culture Vessels

Bioreactors

Consumables

Cell Culture Type

Finite Cell Line Cultures

Infinite Cell Line Cultures

Application

Drug Development

Stem Cell Research

Regenerative Medicine

Cancer Research

End User

Biotech Companies

Research Organizations

Academic Institutions

Region/Country

U.S

Canada

Argentina

Brazil

Mexico

Rest of LATAM

EU-5

Russia

Rest of Europe

India

Thailand

Indonesia

Malaysia

Rest of South Asia

China

Japan

South Korea

Australia

New Zealand

GCC

South Africa

Turkey

Rest of MEA

More Insights on the Automated Cell Culture Systems Market

The study provides compelling insights on automated cell culture systems market on basis of product type (automated cell culture storage equipment, automated cell culture vessels, bioreactors and consumables), cell culture type (finite cell line cultures, infinite cell line cultures), application (drug development, stem cell research, regenerative medicine and cancer research) and end user (biotech companies, research organizations, academic institutes), and across seven major regions.

[ashwetu]

Meticulous Research® Releases New Report on Biopharmaceutical Processing Equipment and Consumables Market: Projected to Reach $83.39

 Meticulous Research®, a globally recognized market intelligence firm, has published a new report forecasting significant growth in the Biopharmaceutical Processing Equipment and Consumables Market. The market is expected to achieve a compound annual growth rate (CAGR) of 9.5% during the forecast period, reaching an estimated $75.72 billion by 2031.

The upward trajectory of this market is largely driven by the expanding biopharmaceutical sector, ongoing biopharmaceutical plant capacity expansions, and the increasing adoption of single-use bioprocessing equipment. However, the market's growth faces headwinds due to the inherent complexities associated with the development and manufacturing of biopharmaceuticals. Despite these challenges, the market presents lucrative opportunities, particularly in emerging economies, as demand for biopharmaceuticals rises, and the industry transitions toward Bioprocessing 4.0 and personalized medicine. Conversely, the substantial capital investment required for biopharmaceutical production remains a critical challenge for market participants.

1     Top Industry Players : https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

The report also provides a comprehensive analysis of the leading companies in the Biopharmaceutical Processing Equipment and Consumables Market, including:

Thermo Fisher Scientific Inc. (U.S.) Headquartered in Massachusetts, Thermo Fisher Scientific operates through four business segments, with its BioProduction segment playing a pivotal role in the biopharmaceutical market. The company’s extensive global presence includes operations across North America, Europe, Asia-Pacific, and other regions.

Agilent Technologies, Inc. (U.S.) Based in California, Agilent Technologies offers a wide range of biopharmaceutical processing equipment through its Life Sciences and Applied Markets business segment. The company’s products are essential for analyzing biological properties in the biopharmaceutical sector.

Sartorius AG (Germany) Sartorius AG, headquartered in Göttingen, Germany, provides a diverse portfolio of products through its Bioprocess Solutions segment. The company maintains a strong global presence, with facilities in key regions such as Europe, North America, and Asia.

Danaher Corporation (U.S.) Operating globally, Danaher Corporation is a leading provider of life sciences and diagnostics products. The company’s Life Sciences segment offers critical biopharmaceutical processing equipment and consumables.

Merck KGaA (Germany) With a legacy dating back to 1668, Merck KGaA operates through its Life Sciences segment to provide innovative solutions in the biopharmaceutical processing market. The company’s extensive global footprint includes operations in over 50 countries.

Additional key players profiled in the report include 3M Company, Bio-Rad Laboratories, Inc., Eppendorf SE, Solaris Biotechnology Srl, and Repligen Corporation, among others. These companies are instrumental in driving innovation and addressing the evolving needs of the biopharmaceutical industry.

Top 10 Blog Here :   https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

2     Market Insights

Meticulous Research®’s report provides a detailed analysis of market trends, opportunities, and challenges. The report examines critical factors influencing market growth, including the adoption of new technologies, strategic partnerships, and evolving regulatory landscapes. It also explores regional market dynamics, highlighting growth prospects in North America, Europe, Asia-Pacific, and other regions.

3     For Further Information

To gain a deeper understanding of the Biopharmaceutical Processing Equipment and Consumables Market, download the full report from Meticulous Research®.

Contact Information: Meticulous Research® Email: sales@meticulousresearch.com Phone: +1-646-781-8004 Connect with us on LinkedIn

[ashwetu]

Meticulous Research® Predicts Biopharmaceutical Processing Equipment and Consumables Market to Surge to $75.72 Billion by 2031

 Meticulous Research®, a globally recognized market intelligence firm, has published a new report forecasting significant growth in the Biopharmaceutical Processing Equipment and Consumables Market. The market is expected to achieve a compound annual growth rate (CAGR) of 9.5% during the forecast period, reaching an estimated $75.72 billion by 2031.

The upward trajectory of this market is largely driven by the expanding biopharmaceutical sector, ongoing biopharmaceutical plant capacity expansions, and the increasing adoption of single-use bioprocessing equipment. However, the market's growth faces headwinds due to the inherent complexities associated with the development and manufacturing of biopharmaceuticals. Despite these challenges, the market presents lucrative opportunities, particularly in emerging economies, as demand for biopharmaceuticals rises, and the industry transitions toward Bioprocessing 4.0 and personalized medicine. Conversely, the substantial capital investment required for biopharmaceutical production remains a critical challenge for market participants.

Top Industry Players : https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

The report also provides a comprehensive analysis of the leading companies in the Biopharmaceutical Processing Equipment and Consumables Market, including:

Thermo Fisher Scientific Inc. (U.S.) Headquartered in Massachusetts, Thermo Fisher Scientific operates through four business segments, with its BioProduction segment playing a pivotal role in the biopharmaceutical market. The company’s extensive global presence includes operations across North America, Europe, Asia-Pacific, and other regions.

Agilent Technologies, Inc. (U.S.) Based in California, Agilent Technologies offers a wide range of biopharmaceutical processing equipment through its Life Sciences and Applied Markets business segment. The company’s products are essential for analyzing biological properties in the biopharmaceutical sector.

Sartorius AG (Germany) Sartorius AG, headquartered in Göttingen, Germany, provides a diverse portfolio of products through its Bioprocess Solutions segment. The company maintains a strong global presence, with facilities in key regions such as Europe, North America, and Asia.

Danaher Corporation (U.S.) Operating globally, Danaher Corporation is a leading provider of life sciences and diagnostics products. The company’s Life Sciences segment offers critical biopharmaceutical processing equipment and consumables.

Merck KGaA (Germany) With a legacy dating back to 1668, Merck KGaA operates through its Life Sciences segment to provide innovative solutions in the biopharmaceutical processing market. The company’s extensive global footprint includes operations in over 50 countries.

Additional key players profiled in the report include 3M Company, Bio-Rad Laboratories, Inc., Eppendorf SE, Solaris Biotechnology Srl, and Repligen Corporation, among others. These companies are instrumental in driving innovation and addressing the evolving needs of the biopharmaceutical industry.

Top 10 Blog Here :   https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

Market Insights

Meticulous Research®’s report provides a detailed analysis of market trends, opportunities, and challenges. The report examines critical factors influencing market growth, including the adoption of new technologies, strategic partnerships, and evolving regulatory landscapes. It also explores regional market dynamics, highlighting growth prospects in North America, Europe, Asia-Pacific, and other regions.

For Further Information

To gain a deeper understanding of the Biopharmaceutical Processing Equipment and Consumables Market, download the full report from Meticulous Research®.

Contact Information: Meticulous Research® Email: sales@meticulousresearch.com Phone: +1-646-781-8004 Connect with us on LinkedIn

[ashwetu]

Meticulous Research® Predicts Biopharmaceutical Processing Equipment and Consumables Market to Surge to $75.72 Billion by 2031

 Meticulous Research®, a globally recognized market intelligence firm, has published a new report forecasting significant growth in the Biopharmaceutical Processing Equipment and Consumables Market. The market is expected to achieve a compound annual growth rate (CAGR) of 9.5% during the forecast period, reaching an estimated $75.72 billion by 2031.

The upward trajectory of this market is largely driven by the expanding biopharmaceutical sector, ongoing biopharmaceutical plant capacity expansions, and the increasing adoption of single-use bioprocessing equipment. However, the market's growth faces headwinds due to the inherent complexities associated with the development and manufacturing of biopharmaceuticals. Despite these challenges, the market presents lucrative opportunities, particularly in emerging economies, as demand for biopharmaceuticals rises, and the industry transitions toward Bioprocessing 4.0 and personalized medicine. Conversely, the substantial capital investment required for biopharmaceutical production remains a critical challenge for market participants.

Top Industry Players : https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

The report also provides a comprehensive analysis of the leading companies in the Biopharmaceutical Processing Equipment and Consumables Market, including:

Thermo Fisher Scientific Inc. (U.S.) Headquartered in Massachusetts, Thermo Fisher Scientific operates through four business segments, with its BioProduction segment playing a pivotal role in the biopharmaceutical market. The company’s extensive global presence includes operations across North America, Europe, Asia-Pacific, and other regions.

Agilent Technologies, Inc. (U.S.) Based in California, Agilent Technologies offers a wide range of biopharmaceutical processing equipment through its Life Sciences and Applied Markets business segment. The company’s products are essential for analyzing biological properties in the biopharmaceutical sector.

Sartorius AG (Germany) Sartorius AG, headquartered in Göttingen, Germany, provides a diverse portfolio of products through its Bioprocess Solutions segment. The company maintains a strong global presence, with facilities in key regions such as Europe, North America, and Asia.

Danaher Corporation (U.S.) Operating globally, Danaher Corporation is a leading provider of life sciences and diagnostics products. The company’s Life Sciences segment offers critical biopharmaceutical processing equipment and consumables.

Merck KGaA (Germany) With a legacy dating back to 1668, Merck KGaA operates through its Life Sciences segment to provide innovative solutions in the biopharmaceutical processing market. The company’s extensive global footprint includes operations in over 50 countries.

Additional key players profiled in the report include 3M Company, Bio-Rad Laboratories, Inc., Eppendorf SE, Solaris Biotechnology Srl, and Repligen Corporation, among others. These companies are instrumental in driving innovation and addressing the evolving needs of the biopharmaceutical industry.

Top 10 Blog Here :   https://meticulousblog.org/top-10-companies-in-biopharmaceutical-processing-equipment-and-consumables-market/

Market Insights

Meticulous Research®’s report provides a detailed analysis of market trends, opportunities, and challenges. The report examines critical factors influencing market growth, including the adoption of new technologies, strategic partnerships, and evolving regulatory landscapes. It also explores regional market dynamics, highlighting growth prospects in North America, Europe, Asia-Pacific, and other regions.

For Further Information

To gain a deeper understanding of the Biopharmaceutical Processing Equipment and Consumables Market, download the full report from Meticulous Research®.

Contact Information: Meticulous Research® Email: sales@meticulousresearch.com Phone: +1-646-781-8004 Connect with us on LinkedIn

[metiresearchinfo]

TOP 10 COMPANIES IN CONTINUOUS BIOPROCESSING MARKET

The continuous bioprocessing market is expected to grow at a CAGR of 23.0% from 2021 to reach $429.12 million by 2028.

The growth of global continuous bioprocessing market is primarily driven by factors such as recent product launches in the continuous bioprocessing space, gradual adoption of continuous manufacturing, and global initiatives supporting the adoption of biopharmaceuticals. The shift towards bioprocessing 4.0, untapped markets in developing countries, and rising adoption of personalized medicines are expected to offer significant market opportunities.

Here are the top 10 companies operating in continuous bioprocessing market

3M Company

3M is a multinational conglomerate with expertise in product development, manufacturing, and marketing across various industries like consumer care, industrial safety, healthcare, and others. The company manages its operations across four business segments: Transportation and Electronics, Safety and Industrial, Consumer, and Health Care. The Health Care business segment offers oral care solutions, medical solutions, health information systems, separation and purification sciences, food safety, and drug delivery system. Separation and purification sciences include a comprehensive range of filtration products intended for the separation, classification, and purification of gases and fluids. The company provides a range of chromatography filters for biopharmaceutical applications like vaccines, recombinant proteins, chemical pharmaceuticals, and plasma fractionation.

3M sells its products through a number of distribution channels, including numerous ecommerce, retailers, traditional wholesalers, jobbers, dealers, and distributors and directly to users. The company operates 64 manufacturing facilities across 29 states in the U.S. Internationally, the company has over 97 manufacturing and converting facilities in 35 countries.

Cytiva

Cytiva is a provider of services and technologies to advance and accelerate the development and production of therapeutics. Previously, the biopharma business of GE Healthcare Life Sciences (U.S.), Cytiva is now a part of Danaher Corporation. The company offers its solutions for bioprocessing, cellular analysis, cell and gene therapy, diagnostics, enterprise solutions, genomics, lab filtration, and protein research. The company’s portfolio of bioprocessing solutions consists of upstream and downstream bioprocessing, enterprise solutions for bioprocessing, and FastTrack bioprocessing services. Upstream and downstream bioprocessing involves solutions for improving Xcellerex bioreactors, HyClone cell culture media, MabSelect chromatography resins, and ÄKTA systems. Enterprise solutions for bioprocessing involve KUBio facilities and Modular FlexFactory platforms for integrated platforms. FastTrack bioprocessing services include process development, collaborative training, and manufacturing services.

Cytiva has its presence across 40 locations covering North America, Europe, Asia, Latin America, and the Middle East, and Africa. As per the company’s data, in 2019, over 75% of biological therapies approved by the U.S. FDA used Cytiva’s technology for manufacturing.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc. is a biotechnology company primarily engaged in accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics, and increasing laboratory productivity. The company operates through its four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company’s life science segment consists of bioscience, genetic sciences, clinical next generation sequencing, and bioproduction. The company’s bioproduction offering includes single use bioproduction solutions, production cell culture media solutions, chromatography products, rapid molecular products, and scalable solutions for the manufacturing of cell therapy-based drugs.

The company sells and markets its products and services through electronic commerce, direct sales force, third party distributors, and customer service professionals. The company serves over 400,000 customers working in the biotech and pharma space, diagnostic labs, hospitals and clinics, research institutions, government agencies, universities, and environmental, industrial quality, and process control settings.

Merck KGaA

Merck KGaA is a science and technology company aimed to improve the health and wellbeing of people and advance their lives through science and technology. The company operates its business through three segments: Healthcare, Life Sciences, and Performance Materials. The Life Sciences business segment is further categorized into Research Solutions, Process Solutions, and Applied Solutions. Process solutions provide drug manufacturers with process development technologies and expertise, including continuous bioprocessing. The company operates in the continuous bioprocessing market through its Process Solutions business unit (a part of the Life Sciences segment).

The Life Science business sector has 59 manufacturing sites across the globe and more than 100 distribution centers. The sector has corporate offices, manufacturing units, and distributors across Argentina, Germany, France, Romania, Colombia, Japan, Brazil, Belgium, Croatia, the U.S., and Iraq, among others. The company’s life science segment serves various clients catered across a range of geographies, namely, North America, Europe, Asia Pacific, MEA, and Latin America.

Sartorious AG

Sartorious AG, assists biopharma research and development and manufacturing companies. The company conducts its operations through two divisions: Lab Product and Services and Bioprocess Solutions. The Bioprocess Solutions division offers products and services for biopharma production. Some of the technologies under Bioprocess Solutions include cell line technologies, bioreactors, cell culture media, products for the separation, purification and concentration, and storage and transportation products.

The company markets its products directly through sales representatives. The company expanded its direct sales operations in the Asia Pacific with the acquisition of a sales partner in Taiwan in 2012, particularly from Bioprocess Solutions. The company’s Bioprocess Solutions segment has a well-developed production network, with the largest production sites located across France, Germany, and Puerto Rico. The company also manufactures in Switzerland, India, the U.K., Tunisia, and the U.S.

Repligen Corporation

Repligen Corporation is a global life science company specializing in the development and commercialization of innovative bioprocessing technologies and systems, increasing flexibility and efficiencies in biologics manufacturing. The company’s bioprocessing business involves four main franchises: Filtration, Chromatography, Process Analytics, and Proteins. The chromatography franchise includes products for development, downstream purification, manufacturing, and quality control of biologics. The company entered the filtration technology market in 2014 after the acquisition of XCell Alternating Tangential Flow (“ATF”) assets from Refine Technology LLC (U.S.), which have applications in continuous cell culture processing. The company also has a portfolio of process analytics products complementing its product offering. Further, through the proteins segment, the company assists upstream bioprocessing.

The company’s bioprocessing products are majorly sold to biopharmaceutical development companies, life sciences companies, and contract manufacturing organizations. The company’s manufacturing facilities are located in Waltham, Massachusetts; Rancho Dominguez, Marlborough, Massachusetts, Texas; California; Irving, Lund, Sweden; Bridgewater, New Jersey; and Weingarten, Germany.

Eppendorf AG

Eppendorf AG is a life science company involved in the manufacturing and selling of laboratory instruments, consumables, and services. The company operates in four business segments: Separation & Instrumentation, Consumables, Liquid Handling, and Lab Solutions, under which it manufactures and sells products like manual and automatic pipettes, centrifuges, dispensers, spectrometers, mixers, DNA amplification equipment, fermenters and bioreactors, ultra-low temperature freezers, shakers, CO2 incubators, cell manipulation systems, single use bioreactor systems and consumables like test tubes, microtiter plates, and pipette tips.

The company has a direct presence in about 26 countries, and it is present in all other markets through distributors. As a part of the innovation initiative, the company had undertaken agile product development across its global operations in 2019, under which the company introduced about 20 products in 2019.

Applikon Biotechnology

Founded in 1973 and is headquartered in the Netherlands, Applikon Biotechnology develops and supplies advanced bioreactor systems from lab scale to pilot and production scale. The company supports the pharma industry and industrial microbiology in upstream processing by implementing scalable platforms from initial screening through full scale development. The company offers cultivation systems, process controls, software, turnkey systems, process analytics, perfusion, and integrated solutions for various industries like bio-fuels, pharma, regenerative medicine, academia, and food. The company’s Applikon BioSep System is a cell retention device for high quality perfusion processes, which uses a high frequency resonant ultrasonic waves for cell separation instead of physical membrane or mesh.

The company underwent facility expansion in June 2017. The company has a global distribution network covering over 35 countries. In December 2019, the company announced an acquisition of 100% shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V. The company has an annual sale of USD 47.61 million (SEK 450 million)

Pall Corporation

Pall Corporation is a manufacturer of high tech separation, filtration, and purification instruments serving diverse needs of customers for various application industries. Pall Life Sciences and Pall Industrial are the primary operating segments of the company. The company’s life sciences business provides products and services that support the discovery, development, and production of medicinal products, including vaccines, biotech drugs, cell therapies, and pharmaceuticals. The life science offerings include depth filtration, sterile filtration, chromatography hardware, and purification platform, and bio containers.

The company is present across 80 locations worldwide. In 2015, Danaher Corporation (U.S.) completed the merger of U.S. based Pentagon Merger Sub, Inc, after which an indirect wholly owned subsidiary of Danaher Corporation, Pall Corporation, was formed.

Bionet

Incorporated in 1999 and headquartered in Mercia, Spain. Bionet is a manufacturer of laboratory, pilot, and industrial equipment and software for the bioprocessing industry. The company also provides bioprocess related services for the companies providing biomolecules through the cell culturing process and microbial fermentation. The company’s portfolio of bioprocessing solutions includes automation software solutions, bioreactors/fermenters, auxiliary equipment like cleaning in place systems, and tangential filtration. For industrial clients, the company provides complete bioproduction plants, integrating the company’s proprietary equipment with technologies like centrifuges, homogenizers from other vendors. The company also provides services like operation and maintenance activity, qualification, and technology election. Bionet is also part of international R&D institutions, organizations, and projects such as CETENMA, ASEBIO, CITEM, BRIDGE2020, GREENPGAS, PROGRAMA “HORIZONTE PYME”, GREEN PROTEIN, and FABRICACIÓN DEVACUNAS. The company has also been ISO 9001:2015, certified by AENOR for its quality management systems.

Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/download-sample-report/cp_id=5079

Authoritative Research on the Continuous Bioprocessing Market – Global Opportunity Analysis and Industry Forecast (2021-2028)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

Recent financial performance

Key products

Significant company strategies

Partnerships and acquisitions

The Impact of COVID-19 on the Continuous Bioprocessing Market

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

Please download report pages and learn more:

Download Free Samlpe

[metiresearchinfo]

Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2028

The continuous bioprocessing market is expected to grow at a CAGR of 23.0% from 2021 to reach $429.12 million by 2028. Continuous bioprocessing involves manufacturing biopharmaceuticals where continuous unit operations are physically connected with minimal hold volume. Some of the major factors driving the growth of this market include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.

COVID-19 Impact Assessment

The COVID-19 pandemic has affected most industries, including the biopharma industry. Changes in the bio/pharmaceutical industry have accelerated as a response to the ongoing COVID-19 pandemic. The biopharma industry is adopting improved strategies to tackle the current pandemic, prepare for future pandemics, and minimize supply disruptions. The industry is witnessing partnerships and collaborations focused on accelerating R&D and implementing flexible, rapid, and modular production processes to speed up the products’ time to market. Such factors are projected to drive the demand for continuous bioprocessing amid the COVID-19 pandemic.

The COVID-19 pandemic has affected most industries, including the biopharma industry. Changes in the bio/pharmaceutical industry have accelerated as a response to the ongoing COVID-19 pandemic. The biopharma industry is adopting improved strategies to tackle the current pandemic, prepare for future pandemics, and minimize supply disruptions. The industry is witnessing partnerships and collaborations focused on accelerating R&D and implementing flexible, rapid, and modular production processes to speed up the products’ time to market. Such factors are projected to drive the demand for continuous bioprocessing amid the COVID-19 pandemic. With the growing number of vaccine and therapeutic candidates in the pipeline, the demand for novel manufacturing approaches, such as continuous processing, is expected to positively impact the market in the long term.

Pharma manufacturers are investing in vaccine development and production. For instance, in June 2020, the Serum Institute of India (India) announced an investment of USD 100 million in the COVID-19 vaccine being developed at Oxford University, in partnership with AstraZeneca Plc. (U.K.), to ensure equitable supply of the AZD1222 vaccine doses to India as well as other low-and-middle-income countries. In December 2020, China-based Sinovac Biotech Ltd. received an investment of USD 515 million from local firm Sino Biopharmaceutical to accelerate the production of a COVID-19 vaccine candidate. Such initiatives are expected to create favorable market opportunities.

As per the Global Vaccine Market Report released by WHO in December 2019, the annual demand for vaccines had reached 3.5 billion doses in 2018. However, with the emergence of COVID-19, this number is expected to reach 9 billion doses of different vaccine modalities by the end of 2021. This sizeable requirement is expected to generate novel approaches like continuous bioprocessing and the use of single-use technologies.

However, the global spread of COVID-19 also adversely impacted operations, sales, and delivery & supply chains. Many countries implemented national lockdowns, shelter-in-place, curfews, travel restrictions, and isolation measures delaying distributions and affecting supply chains of the necessary instruments and consumables, negatively impacting continuous bioprocessing.

Thus, apart from few supply disruptions and operational challenges during the first phase of the pandemic, the overall impact of COVID-19 is expected to be positive on the market with growing pressure from the policymakers to develop novel vaccines and therapies cost-effectively.

                                                 Click here to: Get Free Request Sample Copy of this report

Various initiatives supporting the adoption of biopharmaceuticals is projected to drive the adoption of continuous bioprocessing

The global biosimilars market is fast-growing and possesses strong economic value. Pricing for biosimilars is usually 30-50% lower than that of biologics. This cost advantage gives greater access to biosimilars, further lowering the health expenditure in many countries. As per the Center for Medical Economics and Innovation at the Pacific Research Institute (PRI), U.S., expanding the use of biosimilars to treat serious illnesses like autoimmune diseases or cancer can help reduce the out-of-pocket spending by 17% for the patient.

Between 2017-2024, it is projected that near about biologics worth USD 100 billion will go off patent, creating opportunities for the biosimilars. The U.S. FDA is expecting the review of over 66 biosimilars as 66 biologics are going off-patent between 2020 and 2025. Knowing the high potential in the biosimilars business, market players such as Mylan N.V (U.S.), Biocon Limited (India), and Aurobindo Pharma Limited (India) are investing in biosimilars. Growing developments in the space of biosimilars are further fueled by supportive initiatives across various countries worldwide.

In February 2020, the U.S. FDA transitioned to a new regulatory pathway to boost the competition between biological products. The U.S. FDA and the Federal Trade Commission (FTC) signed a joint statement regarding enhanced collaboration to support a robust marketplace for biological products like biosimilars and interchangeable products.

China and India are among the leading countries in terms of the development and commercialization of biosimilars. The Chinese government offers multiple initiatives facilitating the development and adoption of biosimilars. The Marketing Authorization Holder (MAH) pilot scheme was launched in China, allowing license holders to sell drugs in China using a contract manufacturer, driving innovations and accelerating the speed at which international companies can introduce products in China, facilitating the growth of CDMOs. Such initiatives are driving the adoption of biosimilars globally, thereby positively impacting the demand for continuous bioprocessing technologies.

Active research in the area of personalized therapies to create several opportunities for market growth

Growing advances in proteomic and genomic sciences have boosted the emergence of personalized therapies. The wave of personalized medicines has entered a mainstream clinical approach, changing the identification, classification, or treatment of diseases. The recognition for personalized medicines is growing among the policymakers, driving the innovative approaches of developing and producing personalized therapies. Continuous bioprocessing and greater accuracy through data analytics and monitoring allow for higher concentrations of next-generation biologics drug dosages, enabling more personalized and effective medicines in potentially smaller/less frequent administration and dosages.

With the pharmaceutical industry moving towards the development of personalized therapies, new manufacturing approaches are being adopted to meet the growing market demand. Advancing continuous bioprocessing has emerged as one of the innovative approaches for manufacturing therapies cost-effectively and on a relatively small scale, offering multiple advantages.

Key Findings in the Global Continuous Bioprocessing Market Study:

In 2020, the filtration systems and consumables segment accounted for the largest share of the market

Based on product, the continuous bioprocessing market is segmented into filtration systems & consumables; chromatography systems & consumables; bioreactors; sterilizers; centrifuges; incubators & shakers; mixing systems; cell culture media, buffers, and reagents; and other products. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for the growth of this segment. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion.

The research & development segment is projected to grow at the highest CAGR during the forecast period

Based on application, the continuous bioprocessing market is segmented into commercial and R&D. The rising focus of R&D to develop vaccines and suitable therapies for COVID-19 and growing relevance of mAb manufacturing for the treatment of various diseases are driving the market growth. The R&D in cell and gene therapy is also accelerated, with over 900 candidates in clinical studies. Facility expansions of CROs or CDMOs to advance research in these areas are expected to boost market growth.

In 2020, the pharmaceutical and biotechnology companies segment dominated the global continuous bioprocessing market

Based on end user, the continuous bioprocessing market is segmented into pharmaceutical and biotechnology companies, CDMOs & CMOs, and academic and research institutes. Pharma and biopharma manufacturers are shifting from batch to continuous processing. This process provides considerable benefits to manufacturers by being more cost-effective, requiring less infrastructure, less space, less investment, less staff, all while manufacturing products in the same or perhaps less time than traditional batch methods.

Asia-Pacific: Fastest growing regional market

Based on region, the market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa. The gradually emerging landscape of biopharmaceuticals in Asian countries, CDMO expansions, developments in bioprocessing technologies and partnerships, and collaborations among market players for biopharma manufacturing drives the market growth in Asia-Pacific.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past three years. The key players profiled in the global continuous bioprocessing market report are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain).

Scope of the Report:

Continuous Bioprocessing Market, by Product

Filtration Systems and Consumables

Chromatography Systems and Consumables

Bioreactors

Sterilizers

Centrifuges

Incubators and Shakers

Mixing Systems

Cell Culture Media, Buffers, and Reagents

Other instruments and consumables

Continuous Bioprocessing Market, by Application

Commercial

R&D

Vaccines

mAb production

Recombinant Protein Production

Cell and Gene Therapy Production

Continuous Bioprocessing Market, by End User

Pharmaceutical and Biotechnology Companies

Contract Development and Manufacturing Organizations and Contract Research Organizations

Academic and Research Institutes

Continuous Bioprocessing Market, by Geography

North America

Europe

Asia-Pacific (APAC)

Latin America

Middle East & Africa

U.S.

Canada

Germany

U.K.

France

Italy

Spain

Rest of Europe (RoE)

China

Japan

India

Rest of APAC (RoAPAC)